ReviewBiosensors2026
A Review of SERS-Based Bacterial Detection from Nanomaterials to Integrated Clinical Platforms.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pathogenic bacterial infections remain a persistent global public health crisis. However, traditional clinical detection methods-such as culture-based assays and polymerase chain reaction (PCR)-are often time-consuming and labor-intensive, and they lack sufficient sensitivity for low-abundance pathogens, hindering rapid point-of-care diagnosis. With label-free, ultra-sensitive molecular fingerprinting, Surface-Enhanced Raman Scattering (SERS) has emerged as a powerful tool for rapid pathogen identification. This review summarizes the evolution of SERS-based bacterial detection from fundamental nanomaterials to integrated clinical diagnostic platforms. The article explores four core dimensions: functional integration and enrichment strategies of colloidal probes; structural design and multifaceted capture mechanisms of solid substrates; synergistic advantages of microfluidic systems in enabling automated "sample-to-answer" architectures; and the translational potential of SERS-based lateral flow assays (LFAs) for robust point-of-care testing (POCT). This review reveals a research shift from maximizing electromagnetic enhancement toward overcoming matrix effects in clinical samples and ensuring robustness. In synergy with microfluidics, LFAs, and AI, SERS technology is bridging the bench-to-bedside gap, offering a roadmap for next-generation decentralized, high-precision diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.